Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and ...
Can training your brain's reward circuits strengthen your immune response to vaccination? A new randomised controlled trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results